CDRH 483s Will Include Language Developed Under GMP Initiative
This article was originally published in The Gray Sheet
Executive Summary
FDA is seeking to reconcile device Form 483s with new language being added to drug inspection documents under the auspices of CDER's GMP initiative, according to FDA Assistant Commissioner of Regulatory Affairs Steve Niedelman
You may also be interested in...
Combination Product Oversight Will Be Partly Affected By Drug GMP Initiative
FDA's initiative to enhance pharmaceutical good manufacturing practices will apply to combination products that have biological drug or drug components
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.